Background The percentage of strains of Propionibacterium acnes resistant to antibiotics in acne is increasing in many countries, raising the question of the risks associated with bacterial resistance. Numerous series of cases have been published on European populations of acne patients, but at the moment we still have very few data regarding France.

Objectives The aim of this study was to evaluate the prevalence of P. acnes resistant strains to erythromycin, tetracycline, and doxycycline in a population of French acne patients.

Methods Specimens were collected from 273 patients in 43 centers located throughout France (12 hospitals and 31 private office practices).

Results 75.1% of the patients were carriers of P. acnes strains resistant to erythromycin and 9.5% to tetracycline. One hundred percent of strains resistant to tetracycline were also resistant to doxycycline. There was no significant difference among the regions and between patients followed in hospital or private office.

Conclusions It clearly appears that the percentage of patients with P. acnes strains resistant to erythromycin is similar to that in other countries, but lower for tetracycline or doxycycline in comparison to other European countries.

References

1 Bonnetblanc JM. Doxycycline. Ann Dermatol Venereol 2002; 129: 874–882.
CAS PubMed Web of Science® Google Scholar
2 Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130–134.
10.1159/000017846
CAS PubMed Web of Science® Google Scholar
3 Brown JM, Poston SM. Resistance of propionibacteria to antibiotics used in the treatment of acne. J Med Microbiol 1983; 16: 271–280.
10.1099/00222615-16-3-271
CAS PubMed Web of Science® Google Scholar
4 Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–45.
10.1016/S0190-9622(83)70005-8
CAS PubMed Web of Science® Google Scholar
5 Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004; 364: 2188–2195.
10.1016/S0140-6736(04)17591-0
CAS PubMed Web of Science® Google Scholar
6 Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(Suppl. 53): 4–8.
10.1046/j.1365-2133.1998.1390s3004.x
CAS PubMed Web of Science® Google Scholar
7 Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840–848.
10.1046/j.1365-2133.2002.04690.x
CAS PubMed Web of Science® Google Scholar
8 Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467–478.
10.1046/j.1365-2133.2003.05067.x
CAS PubMed Web of Science® Google Scholar
9 Noyon V, Legallou F, Richet H, et al. The resistance of Propionibacterium acnes and Staphylococcus epidermidis to cyclines. The Research and Study Group on Acne. Ann Dermatol Venereol 1998; 125: 885–887.
CAS PubMed Web of Science® Google Scholar
10 Dreno B, Reynaud A, Moyse D, et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549–553.
CAS PubMed Web of Science® Google Scholar
11 Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79: 9–25.
PubMed Web of Science® Google Scholar
12 Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54–56.
10.1159/000067822
CAS PubMed Web of Science® Google Scholar
13 Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999; 9: 25–28.
CAS PubMed Web of Science® Google Scholar
14 Nishijima S, Kurokawa I, Katoh N, et al. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000; 27: 318–323.
10.1111/j.1346-8138.2000.tb02174.x
CAS PubMed Google Scholar
15 Dreno B, Daniel F, Allaert FA, et al. Acne: evolution of the clinical practice and therapeutic management of acne between 1996 and 2000. Eur J Dermatol 2003; 13: 166–170.
PubMed Web of Science® Google Scholar
16 Oprica C, Lofmark S, Lund B, et al. Genetic basis of resistance in Propionibacterium acnes strains isolated from diverse types of infection in different European countries. Anaerobe 2005; 11: 137–143.
10.1016/j.anaerobe.2005.01.005
CAS PubMed Web of Science® Google Scholar
17 Coenye T, Peeters E, Nelis HJ. Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol 2007; 158: 386–392.
10.1016/j.resmic.2007.02.001
CAS PubMed Web of Science® Google Scholar
18 Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339–346.
10.1046/j.1365-2133.2001.03956.x
CAS PubMed Web of Science® Google Scholar
19 Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005; 11: 204–213.
10.1111/j.1469-0691.2004.01055.x
CAS PubMed Web of Science® Google Scholar
20 Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992; 126: 586–590.
10.1111/j.1365-2133.1992.tb00104.x
PubMed Web of Science® Google Scholar
21 Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–336.
10.1111/j.1365-2133.1994.tb02929.x
PubMed Web of Science® Google Scholar
22 Pierard-Franchimont C, Goffin V, Visser JN, et al. A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex. Eur J Clin Pharmacol 1995; 49: 57–60.
10.1007/BF00192359
CAS PubMed Web of Science® Google Scholar
23 Dreno B, Foulc P, Reynaud A, et al. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol 2005; 15: 152–155.
CAS PubMed Web of Science® Google Scholar
24 Holland KT, Bojar RA, Cunliffe WJ, et al. The effect of zinc and erythromycin on the growth of erythromycin-resistant and erythromycin-sensitive isolates of Propionibacterium acnes: an in-vitro study. Br J Dermatol 1992; 126: 505–509.
10.1111/j.1365-2133.1992.tb15124.x
CAS PubMed Web of Science® Google Scholar
25 Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134: 107–113.
10.1046/j.1365-2133.1996.d01-733.x
CAS PubMed Web of Science® Google Scholar
26 Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004; 5: 261–265.
10.2165/00128071-200405040-00005
PubMed Web of Science® Google Scholar
27 Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis 2001; 67: 21–24.
CAS PubMed Web of Science® Google Scholar
28 Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004; 14: 391–399.
PubMed Web of Science® Google Scholar
29 Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49(Suppl. 2): 164–167.
10.2165/00003495-199500492-00027
CAS PubMed Google Scholar
30 Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 48–55.
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume49, Issue3

March 2010

Pages 283-288

Bacterial resistance in French acne patients

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Bacterial resistance in French acne patients

Abstract

References

Citing Literature

References

Related

Information